Nifedipine attenuation of abdominal aortic aneurysm in hypertensive and non-hypertensive mice: Mechanisms and implications

Journal of Molecular and Cellular Cardiology

Volumn 87, Issue , 2015, Pages 152-159

  Miao, Xiao Niu ^a,b   Siu, Kin Lung ^a   Cai, Hua ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Abdominal aortic aneurysm; Angiotensin II; Blood pressure; ENOS recoupling; Hph 1 mice; NADPH oxidase (NOX); Nifedipine

Indexed keywords

ANGIOTENSIN II; CALCIUM CHANNEL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NIFEDIPINE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL L TYPE; NOS3 PROTEIN, MOUSE;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ECHOGRAPHY; ENDOTHELIUM CELL; HYPERTENSION; INCIDENCE; LOW DRUG DOSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; AORTA; AORTIC ANEURYSM, ABDOMINAL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHENYLKETONURIAS; TRANSGENIC MOUSE;

MUS;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; AORTIC ANEURYSM, ABDOMINAL; CALCIUM CHANNELS, L-TYPE; HUMANS; HYPERTENSION; MICE; MICE, TRANSGENIC; NADPH OXIDASE; NIFEDIPINE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHENYLKETONURIAS;

EID: 84940023403     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.07.031     Document Type: Article

References (37)

1. Li X., Zhao G., Zhang J., Duan Z., Xin S. Prevalence and trends of the abdominal aortic aneurysms epidemic in general population - a meta-analysis. PLoS ONE 2013, 8:e81260.
2. Trivedi D.B., Loftin C.D., Clark J., Myers P., DeGraff L.M., Cheng J., et al. beta-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice. Circ. Res. 2013, 112:1219-1229.
3. Cassis L.A., Gupte M., Thayer S., Zhang X., Charnigo R., Howatt D.A., et al. ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1660-H1665.
4. Thomas M., Gavrila D., McCormick M.L., Miller F.J., Daugherty A., Cassis L.A., et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 2006, 114:404-413.
5. Hosokawa Y. Effects of angiotensin receptor blocker and calcium channel blocker on experimental abdominal aortic aneurysms in a hamster model. Kurume Med. J. 2010, 57:1-8.
6. Ruegg G., Mason R.H., Hardinge M., Perkins J., Husmann M., Russi E.W., et al. Augmentation index and central aortic blood pressure in patients with abdominal aortic aneurysms. J. Hypertens. 2010, 28:2252-2257.
7. Chen X., Rateri D.L., Howatt D.A., Balakrishnan A., Moorleghen J.J., Morris A.J., et al. Amlodipine reduces AngII-induced aortic aneurysms and atherosclerosis in hypercholesterolemic mice. PLoS ONE 2013, 8:e81743.
8. Mieth A., Revermann M., Babelova A., Weigert A., Schermuly R.T., Brandes R.P. L-type calcium channel inhibitor diltiazem prevents aneurysm formation by blood pressure-independent anti-inflammatory effects. Hypertension 2013, 62:1098-1104.
9. Kurobe H., Matsuoka Y., Hirata Y., Sugasawa N., Maxfield M.W., Sata M., et al. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects. J. Thorac. Cardiovasc. Surg. 2013, 146:1501-1508.
10. Gao L., Siu K.L., Chalupsky K., Nguyen A., Chen P., Weintraub N.L., et al. Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid. Hypertension 2012, 59:158-166.
11. Siu K.L., Miao X.N., Cai H. Recoupling of eNOS with folic acid prevents abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E null mice. PLoS ONE 2014, 9:e88899.
12. Tomita N., Yamasaki K., Izawa K., Kunugiza Y., Osako M.K., Ogihara T., et al. Inhibition of experimental abdominal aortic aneurysm progression by nifedipine. Int. J. Mol. Med. 2008, 21:239-244.
13. Huang W., Alhenc Gelas F., Osborne-Pellegrin M.J. Protection of the arterial internal elastic lamina by inhibition of the renin-angiotensin system in the rat. Circ. Res. 1998, 82:879-890.
14. Cohen J.R., Faust G., Tenenbaum N., Sarfati I., Rogowsky P., Wise L. The calcium messenger system and the kinetics of elastase release from human neutrophils in patients with abdominal aortic aneurysms. Ann. Vasc. Surg. 1990, 4:570-574.
15. Boyle J.R., Loftus I.M., Goodall S., Crowther M., Bell P.R., Thompson M.M. Amlodipine potentiates metalloproteinase activity and accelerates elastin degradation in a model of aneurysmal disease. Eur. J. Vasc. Endovasc. Surg. 1998, 16:408-414.
16. Gao X., Iwai M., Inaba S., Tomono Y., Kanno H., Mogi M., et al. Attenuation of monocyte chemoattractant protein-1 expression via inhibition of nuclear factor-kappaB activity in inflammatory vascular injury. Am. J. Hypertens. 2007, 20:1170-1175.
17. Sakurada T., Ishizawa K., Imanishi M., Izawa-Ishizawa Y., Fujii S., Tominaga E., et al. Nitrosonifedipine ameliorates angiotensin II-induced vascular remodeling via antioxidative effects. Naunyn Schmiedebergs Arch. Pharmacol. 2013, 386:29-39.
18. Yamamoto E., Nakamura T., Kataoka K., Tokutomi Y., Dong Y.F., Fukuda M., et al. Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. Biochem. Biophys. Res. Commun. 2010, 403:258-263.
19. Ding Y., Vaziri N.D. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J. Pharmacol. Exp. Ther. 2000, 292:606-609.
20. Berkels R., Egink G., Marsen T.A., Bartels H., Roesen R., Klaus W. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001, 37:240-245.
21. Chen X.N., Xu J., Feng Z., Fan M., Han J.Y., Yang Z. Simvastatin combined with nifedipine enhances endothelial cell protection by inhibiting ROS generation and activating Akt phosphorylation. Acta Pharmacol. Sin. 2010, 31:813-820.
22. Xu B., Xiao-hong L., Lin G., Queen L., Ferro A. Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br. J. Pharmacol. 2002, 136:375-382.
23. Touyz R.M. Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz. J. Med. Biol. Res. 2004, 37:1263-1273.
24. Chalupsky K., Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9056-9061.
25. Dikalova A.E., Gongora M.C., Harrison D.G., Lambeth J.D., Dikalov S., Griendling K.K. Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium-dependent relaxation via eNOS uncoupling. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H673-H679.
26. Bee K.J., Wilkes D.C., Devereux R.B., Basson C.T., Hatcher C.J. TGFbetaRIIb mutations trigger aortic aneurysm pathogenesis by altering transforming growth factor beta2 signal transduction. Circ. Cardiovasc. Genet. 2012, 5:621-629.
27. Lindsay M.E., Dietz H.C. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 2011, 473:308-316. 10.1038/nature10145.
28. Svensjo S., Bjorck M., Gurtelschmid M., Djavani Gidlund K., Hellberg A., Wanhainen A. Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation 2011, 124:1118-1123.
29. Mani K., Lees T., Beiles B., Jensen L.P., Venermo M., Simo G., et al. Treatment of abdominal aortic aneurysm in nine countries 2005-2009: a vascunet report. Eur. J. Vasc. Endovasc. Surg. 2011, 42:598-607.
30. Roddy S.P. Family history of aortic aneurysm is an independent risk factor for more rapid growth of small abdominal aortic aneurysms in Japan. J. Vasc. Surg. 2015, 61:566.
31. Kent K.C., Zwolak R.M., Egorova N.N., Riles T.S., Manganaro A., Moskowitz A.J., et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J. Vasc. Surg. 2010, 52:539-548.
32. Brady A.R., Thompson S.G., Fowkes F.G., Greenhalgh R.M., Powell J.T. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004, 110:16-21.
33. Lederle F.A., Wilson S.E., Johnson G.R., Reinke D.B., Littooy F.N., Acher C.W., et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N. Engl. J. Med. 2002, 346:1437-1444.
34. Wang S., Zhang C., Zhang M., Liang B., Zhu H., Lee J., et al. Activation of AMP-activated protein kinase alpha2 by nicotine instigates formation of abdominal aortic aneurysms in mice in vivo. Nat. Med. 2012, 18:902-910.
35. Ishii N., Matsumura T., Kinoshita H., Fukuda K., Motoshima H., Senokuchi T., et al. Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1598-1605.
36. Matsumori A., Nishio R., Nose Y. Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells. Circ. J. 2010, 74:567-571.
37. Takahashi K., Matsumoto Y., Do e Z., Kanazawa M., Satoh K., Shimizu T., et al. Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation. PLoS ONE 2013, 8:e72558.